All In Biotech

Drug Trial Radar · NCT06363994

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) Vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 476 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

476

Planned (sponsor's estimate)

Start

May 29, 2024

Primary completion

Jun 25, 2031

Study completion Jun 25, 2032

Sponsor

Lead sponsor
InnoCare Pharma Inc.Industry
Sponsor type
Industry
First posted
Apr 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)

Conditions

  • Mantle Cell Lymphoma

Interventions

  • OrelabrutinibDrug

    Eligible patients will receive Orelabrutinib orally as per the protocol,until disease progression or other reasons for treatment discontinuation,whichever comes first.

  • Bendamustine InjectionDrug

    Eligible patients will receive Bendamustine by injection as per the protocol

  • RituximabDrug

    Eligible patients will receive Rituximab by injection as per the protocol

  • Orelabrutinib PlaceboDrug

    Eligible patients will receive Orelabrutinib Placebo orally as per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: 28 days
  2. Progression-free Survival (PFS) for Arm A vs. Arm BTime frame: Approximately 7 years

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, China · Recruiting

  • First Hospital of Jilin University

    Changchun, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • The First People's Hospital of Changzhou

    Changzhou, China · Not yet recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, China · Not yet recruiting

  • Chongqinq Cancer Hospital

    Chongqing, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China · Not yet recruiting

  • The second Hospital of Dalian Medical University

    Dalian, China · Not yet recruiting

  • Fujing Cancer Hospital

    Fuzhou, China · Recruiting

  • Union Hospital Affiliated to Fujian Medical University

    Fuzhou, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • Zhejiang University Medical School affiliated to the first Hospital

    Hangzhou, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, China · Not yet recruiting

  • Shandong Provincial Hospital

    Jinan, China · Not yet recruiting

  • The First Affiliated Hospital of Ningbo University

    Jinan, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University

    Nanjing, China · Not yet recruiting

  • Cancer Hospital Affiliated to Fudan University

    Shanghai, China · Not yet recruiting

  • Huashan Hospital of Fudan University

    Shanghai, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, China · Not yet recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, China · Not yet recruiting

  • Shanxi Cancer Hospital

    Taiyuan, China · Not yet recruiting

  • Tianjin Cancer Hospital

    Tianjin, China · Recruiting

  • The Tumor Hospital Affiliated to Xinjiang Medical University

    Ürümqi, China · Recruiting

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and

    Wuhan, China · Recruiting

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and

    Wuhan, China · Not yet recruiting

  • The First Affiliated Hospital of the PLA Air Force Military Medical University (Xijing Hospital)

    Xi'an, China · Not yet recruiting

  • The Second Affiliated Hospital Of Xi'an Jiaotong University

    Xi'an, China · Not yet recruiting

  • Yibin Second People's Hospital

    Yibin, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.